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Abstract
BACKGROUND: The effective radioiodine treatment of patients 
with DTC is possible only after raising the TSH value over 
30 μUI/ml. This effect might be obtained by either endogenous 
or exogenous stimulation. The aim of this study was to evaluate 
differences in 131I biokinetics of selected regions of interest (ROIs) 
in cases of endogenous and exogenous stimulation. 
MATERIAL AND METHODS: Two groups of 50 patients were 
enrolled in the study. All patients were treated with 3.7 GBq of 
131I; the first group after thyroid hormone withdrawal (THW), the 
second group after rhTSH administration (rhTSH). On the basis 
of post-treatment images, the uptake ratios over selected ROIs 
(thyroid remnants, mediastinum, liver, stomach, abdomen, and 
whole-body) were compared between groups. 
RESULTS: In the case of uptake over the whole-body and the 
liver, statistically significant higher values were received for the 
THW group. For the remaining regions, the differences between 
groups were statistically insignificant, but uptake ratios in the 
rhTSH group were generally numerically lower compared to 
the THW group. 
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CONCLUSIONS: The revealed difference in radioiodine bi-
okinetics after thyroid hormone withdrawal or administration of 
recombinant human TSH may influence many important aspects 
of patients with DTC treatment, such as the choice of proper thera-
peutic scheme, the cost of therapy, and the dose assessment.
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Introduction
In patients with differentiated thyroid carcinoma (DTC), 
efficient treatment with radioiodine complementary to radical 
surgery is possible only on condition that the TSH value is over 
30 μUI/ml. For many years, this effect was obtained by endog-
enous stimulation, which means that L-thyroxine (LT4) was with-
drawn for at least four weeks before the planned treatment with 
131I. Recently, exogenous stimulation of TSH has become possible 
after intramuscular injection of recombinant human TSH, rhTSH 
(Thyrogen, Genzyme, Cambridge, MA) 24 h and 48 h before 
radioiodine treatment.
At first, recombinant human TSH was only approved for the 
stimulation of serum Tg and whole-body scintigraphy (WBS), 
to be performed during post-surgical follow-up and for patient 
staging. Next, many small clinical studies revealed that in low risk 
patients (pT1-2 N0M0) thyroid remnant ablation using rhTSH and 
thyroid hormone withdrawal (THW) methods had a similar rate of 
effective ablation. These findings were finally confirmed by a large 
multicentre controlled randomized study conducted in 2006 [1].
The aim of this study was to evaluate differences in the 131I 
biokinetics of selected regions of interest (ROIs) in cases of endog-
enous and exogenous stimulation in patients from our Department.
Material and methods
A hundred patients were qualified for complementary treat-
ment with 131I in the Endocrinology Department of University Hos-
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pital in Krakow because of DTC in the low stage of the disease 
(pT1aN0M0, pT1bN0M0, pT2N0M0). All patients received the same 
radioiodine activity, 3.7 GBq (100 mCi).
The THW group consisted of 50 patients (mean age 57 years, 
SD 13 years, min 29 years, max 79 years). Papillary thyroid car-
cinoma and follicular thyroid carcinoma were diagnosed in 83% 
and 17% of patients, respectively. In this group of patients, thyroid 
hormone treatment was withheld for 4–6 weeks before radioiodine 
therapy, until the patient’s TSH was above the required level (mean 
TSH level 68 μIU/ml, SD 35 μIU/ml).
The rhTSH group also consisted of 50 patients (mean age 54 
years, SD 16 years, min 19 years, max 77 years). Papillary thyroid 
carcinoma and follicular thyroid carcinoma were diagnosed in 86% 
and 14% of patients, respectively. In this group, the patients con-
tinued receiving L-thyroxine therapy after radical surgery of the 
thyroid. The Thyrogen was administered intramuscularly 48 h and 
24 h before thyroid remnant ablation, in accordance with Polish 
standards [2].
Post-treatment whole-body imaging was performed in all 
patients seven days after 131I administration. All images were 
acquired using a dual-head, large field of view E.CAM gamma 
camera (Siemens, 2000) with high-energy (HE) collimators. The 
camera settings were as follows: 1024 × 256 matrix, 8-cm/min 
scan speed, with autocontour, without scatter correction.
Between the groups, on the basis of AP scans, counts over 
selected regions of the body to counts over the background re-
gion ratios (uptake ratios) were compared. Such regions of inter-
est (ROIs) as: region over the thyroid remnants (thyroid/backg), 
mediastinum (mediastinum/backg), l iver (l iver/backg), 
stomach (stomach/backg), abdomen (abdomen/backg), 
and whole-body (WB/backg), were chosen (Figure 1). The 
background was estimated from counts over the right thigh 
re-calculated on the same number of pixels as was assessed 
in the selected ROI.
Statistical analysis was performed by U Mann-Whitney test at 
a 95% confidence level.
Results
In the case of WB/backg ratios, statistically significant higher 
values were received for the THW group, 0.90 ± 0.69, com-
pared with the rhTSH group, 0.52 ± 0.47 (Figure 2). Taking into 
consideration the thyroid/backg ratios, the difference between 
groups was statistically insignificant (THW group, 25.54 ± 36.21; 
rhTSH group, 27.64 ± 30.14).
For mediastinum and stomach, differences between the 
groups were statistically insignificant (mediastinum/backg — THW 
group, 3.01 ± 1.50; rhTHS group, 2.57 ± 0.86; stomach/backg 
— THW group, 4.70 ± 5.13; rhTSH group, 2.92 ± 1.02). For abdo-
men/backg ratios the same statistically insignificant results were 
observed (THW group, 0.84 ± 0.32; rhTSH group, 0.75 ± 0.19). 
In the case of liver/backg ratios, statistically significant higher val-
ues were also received for the THW group, 4.56 ± 1.66, compared 
with rhTSH group, 3.60 ± 0.89 (Figure 3).
Figure 1. Localization of selected regions of interest. A. Endogenous stimulation, THW group; B. Exogenous stimulation, rhTSH group.
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Discussion
This present study is focused on an assessment of the dif-
ferences in 131I biokinetics in cases of endogenous and exog-
enous stimulation of patients with DTC.
In previous publications concerned with the evaluation of 
the biokinetics of radioiodine, mainly in thyroid remnant localiza-
tions and in the whole-body after the discussed DTC treatment 
schemes, different sophisticated procedures were used. In this pa-
per, a new, simpler method for a number of different regions of 
interest was described. The result obtained for whole body region 
of interest is concordant with previous reports, finding that 131I 
is excreted from the body significantly faster after an exoge-
nous stimulation of thyroid stimulating hormone level. Furthermore, 
for the thyroid remnants region, the same level of tracer uptake 
was found for both therapeutic schemes [3, 4]. Despite the lack 
of statistically significant results for other regions (except the liver), 
uptake ratios in the rhTSH group were always numerically lower 
compared with the THW group. This might be interpreted such that 
after an rhTSH administration most human organs demonstrated 
faster radioiodine clearance because of the short-term influence 
of a factor which stimulated the high TSH level in patients without 
withdrawal of L-Tyroxine. So it is likely the patients’ hyperthyroid 
state influenced the results. The only statistically significant dif-
ference between the groups was observed for the liver, which 
is an organ with a very high metabolism. This may perhaps be 
related to the fact that iodine contained in organic compounds un-
dergoes deiodination mainly in this organ. On the other hand, in 
the THW group, after the withdrawal of L-Tyroxine, a slow rising of 
the TSH level is observed with simultaneous slow passing of all 
cells into a clinically manifested hypothyroid state.
Nowadays, the use of Thyrogen is only approved for pa-
tients with a low stage of the disease (pT1-2 N0M0). An observed 
faster removal of radioiodine after rhTSH administration might be 
a reason for delivering an insufficient radiation dose to metastases, 
which is crucial for their effective sterilization. So, taking into ac-
count patients with higher stages of DTC, this issue should be 
considered very carefully. Approval for exogenous stimulation 
should undeniably be confirmed by positive results from a multi-
centre controlled randomized study with a large group of patients.
Our results might be also considered in respect of the treatment 
cost. Faster elimination of radioiodine in the rhTSH group might 
permit patients a shorter stay in hospital and thus a reduction in 
the overall cost. Many factors might influence the profitability of the 
treatment. To confront two therapeutic schemes, building a Mar-
cov model is a well-accepted statistical and economical technique 
for comparing cost-effectiveness. In the literature, only three manu-
scripts considered this problem, and they all showed a preferable 
overall cost for exogenous stimulation [5–7]. A simpler analysis, 
which was performed in a French hospital, is also mentioned. The 
parameter considered in order to discharge the patient from hos-
pital was a level of body residual activity lower than 400 MBq [8]. 
It was clearly shown that exogenous stimulation reduced patients’ 
average stay by one day. The cost of this therapeutic scheme is still 
higher than endogenous stimulation, but a shorter hospitalization 
allows for a 57% compensation of the Thyrogen cost for one patient. 
Preparing patients with rhTSH might be cost-effective in developed 
countries, but it should be stressed that this statement is only true 
in the case of proper estimation of the remaining treatment costs. 
The next problem connected with our result is the potential 
difference in average absorbed dose for healthy organs, which 
is delivered by 131I radiation during thyroid remnant ablation, after 
endogenous and exogenous stimulation of the TSH level. Currently 
just one paper has been published concerning a full estimate of 
the radiation dose for healthy organs only in the case of rhTSH 
stimulation [9]. However, this issue is very important from a radia-
tion safety point of view and should be considered more carefully 
in future [10, 11].
Important information could be also obtained from compart-
ment models for radionuclide kinetics, an element of patient dose 
estimates. The principle of utilizing compartment modelling is to 
find solutions for the differential equations and calculate the trans-
fer coefficients between compartments. These constants describe 
the degree and rapidity of compartment interactions. They are 
estimated on the basis of each tracer biokinetic measurement. In 
connection with our results, the difference in values of estimated 
transfer coefficients might be observed for endogenous and ex-
ogenous therapeutic schemes. Hence it is crucial to know which 
therapeutic scheme the compartment model was set for.
Conclusions
The revealed difference in radioiodine biokinetics after thyroid 
hormone withdrawal or administration of recombinant human 
Figure 2. WB/backg ratios for both groups. Figure 3. Liver/backg ratios for both groups.
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TSH may influence many important aspects of treatment for 
patients with DTC.
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